TheraRadar
← Back
Data updated: Mar 29, 2026

DAIICHI

OncologyCardiovascularGastroenterology
Pharma

DAIICHI is a pharmaceutical company focused on Oncology, Cardiovascular, Gastroenterology.

1997
Since
1
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 69%
0 drugs Phase 3: 22 Phase 2: 22 Phase 1: 43
Cardiovascular 16%
0 drugs Phase 3: 9 Phase 2: 2 Phase 1: 2
Gastroenterology 8%
0 drugs Phase 3: 2 Phase 2: 3 Phase 1: 6
Respiratory 5%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 2
Metabolic 2%
0 drugs Phase 2: 3

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Cardiovascular
BRACCO specialty
Cardiovascular, Oncology, Metabolic, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Metabolic